Clinical Trial Update: IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on IBI363 combined with chemotherapy as neoadjuvant therapy for initially unresectable stage III non-small cell lung cancer; recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• IBI-363

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Unresectable Stage III Non-small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING